

Asymmetric Total Synthesis and Formal Total Synthesis of the Antitumor Sesquiterpenoid (+)-Eremantholide A


Yi Li and Karl J. Hale*

The UCL Center for Chemical Genomics, The Christopher Ingold Laboratories,
The Chemistry Department, University College London, 20 Gordon Street,
London WC1H 0AJ, UK

k.j.hale@ucl.ac.uk

Received January 11, 2007

ABSTRACT



A new asymmetric total synthesis of (+)-eremantholide A is reported in which a Hoveyda–Grubbs ring-closing metathesis (RCM) reaction is used to assemble the nine-membered oxonin ring, and an enolate alkylation between the 3(2*H*)-furanone 2 and O-triflate 3 is exploited for C(9)–C(10) bond construction. An Evans asymmetric aldol reaction and a Sharpless asymmetric epoxidation served to stereoselectively install the C(6), C(7), and C(8) stereocenters of the target structure.

(+)-Eremantholide A is a structurally novel tumor-inhibiting germacranolide obtained from *Eremanthus elaeagnus*, a rare woody composite found in Brazil.¹ Ever since its initial discovery in 1975 by Le Quesne and Brennan, (+)-eremantholide A has elicited significant synthetic interest² on account of its pronounced antitumor effects against human KB nasopharyngeal carcinoma^{1,3} and its architecturally intriguing structure which provides a significant challenge for asymmetric total synthesis.

(1) (+)-Eremantholide A isolation, structure determination, and initial antitumor evaluation: (a) Raffauf, R. F.; Huang, P.-K. C.; Le Quesne, P. W.; Levery, S. B.; Brennan, T. F. *J. Am. Chem. Soc.* **1975**, *97*, 6884. (b) Le Quesne, P. W.; Levery, S. B.; Menachery, M. D.; Brennan, T. F.; Raffauf, R. F. *J. Chem. Soc., Perkin Trans. 1* **1978**, 1572.


(2) For past total syntheses of (+)-eremantholide A, see: (a) Boeckman, R. K., Jr.; Yoon, S. K.; Heckendorn, D. K. *J. Am. Chem. Soc.* **1991**, *113*, 9682. (b) Takao, K.; Ochiai, H.; Yoshida, K.; Hashizuka, T.; Koshimura, H.; Tadano, K.; Ogawa, S. *J. Org. Chem.* **1995**, *60*, 8179.

(3) Hladon, B.; Twardowski, T. *Pol. J. Pharmacol. Pharm.* **1979**, *31*, 35.

Notwithstanding (+)-eremantholide A first being isolated more than 30 years ago, the signal transduction pathways and genes that it controls (within human cancer cells) remain undefined,⁴ and its potential for inhibiting the growth of xenografted solid human tumors in mice has yet to be demonstrated. In connection with our own proposed studies in this area and to facilitate future analogue development, we recently opted to devise a new asymmetric total synthesis of (+)-eremantholide A and, herein, now report success in this venture with a route that exploits high-dilution ring-closing metathesis (RCM) to close the highly strained nine-membered oxonin ring present within the target.


Our retrosynthetic planning for (+)-eremantholide A (Scheme 1) disassembled the molecule across its C(4)–C(5)

(4) Although 15-acetoxy-eremantholide B inhibits NF-κB at 5 µM in Jurkat T cells, (+)-eremantholide A does not inhibit this target at the concentrations needed to inhibit cancer cell growth. See: Rüngeler, P.; Castro, V.; Mora, G.; Gören, N.; Vichniewski, W.; Pahl, H. L.; Merfort, I.; Schmidt, T. *J. Bioorg. Med. Chem.* **1999**, *7*, 2343.



Compound **24** was readily reduced to **11** with DIBAL-H in PhMe/CH₂Cl₂ at -78 °C over a 1.5 h period. We found

(12) De Mico, A.; Margarita, R.; Parlanti, L.; Vescovi, A.; Piancatelli, G. *J. Org. Chem.* **1997**, 62, 6974.



alcohol **25**. Again, the latter was produced with high stereocontrol, as essentially a single diastereoisomer. It was immediately iodinated at room temperature with Ph_3P , I_2 , and imidazole¹³ in THF and MeCN. Significantly, the inclusion of MeCN proved critical to the success of this reaction, enabling the desired iodo-epoxide **10** to be formed efficiently in good yield (97%). Treatment of **10** with Zn dust in MeOH then effected the desired reductive elimination to provide the allylic alcohol **26** in 91% yield. O-Desilylation with *n*-Bu₄NF subsequently provided **9**.

Although the direct conversion of epoxy alcohol **25** into **26** was examined, using Yadav's titanocene chloride (Cp₂-TiCl/THF) reduction procedure,¹⁴ sadly, we were unable to detect any of **26** in the reaction mixture.

The time had now come for us to attempt the all-important chemoselective oxidation of **9** to the chiral butyrolactone **7**. After abortively screening a number of normally quite selective oxidants for generating γ -butyrolactones from 1,4-diols, including TPAP/NMO,¹⁵ we eventually found that the catalytic TEMPO/BAIB oxidation system^{12,16} could very cleanly deliver the desired lactone **7** in 94% yield. We were now in an excellent position to complete the synthesis of alcohol **6** (Scheme 3). Initially, we successfully C-acylated **7** with **8** and thereafter C-methylated the resulting β -keto ester with MeI (see Scheme 1) but observed that the subsequent Fischer glycosidation with MeOH/(MeO)₃CH/PPTS did not yield any of the desired methyl glycoside **6**. Instead, an internal acetal was formed involving the C(9) oxygen (for the precise structure of this undesired product, see structure **45** on pages 163–170 of our Supporting Information).

A decision was therefore made to remove the cyclohexylidene grouping from **7** with 1,3-propanedithiol and $\text{BF}_3\text{-Et}_2\text{O}$ ^{10,17} (Scheme 3), and selective O-pivaloylation was subsequently attempted on the C(9) OH of diol **27**. Following O-silylation of the product monopivaloate with Et_3SiOTf , the desired C-acylation of **28** proceeded admirably using $\text{LiN}(\text{SiMe}_3)_2$ as the base and **8** as the electrophile. The enolate derived from **29** was thereafter reacted with MeI to give **30**. Exposure of **30** to PPTS/MeOH/ $(\text{MeO})_3\text{CH}$ now cleaved the TES group from O(8) and brought about the desired Fischer glycosidation at C(16) to give **31**. The Piv group was detached from **31** with NaOMe/MeOH, and alcohol **6** was converted into iodide **5** (see Scheme 1 for this structure) by successive O-mesylation and displacement with NaI/butanone at reflux. Unfortunately, iodide **5** proved unreactive toward all the metal enolates that we prepared from **2**. We therefore conducted all subsequent alkylation chemistry with the O-triflate **3**, analogously to Tadano et al.^{2b}

Initially, we used a “chiral” lithium enolate generated from **2** with lithium bis[(*S*)- α -methylbenzylamide]¹⁶ in PhMe at

it necessary to keep the temperature of this reduction at -78°C throughout, otherwise unwanted cleavage of the primary TBDPS group began to occur, even at temperatures as low as -40°C . However, by adhering to the -78°C procedure that we have outlined (in the Supporting Information), excellent results (86% yield) were generally obtained.

With the desired allylic alcohol **11** in hand, we next investigated the Sharpless AE⁷ needed to secure 2,3-epoxy

- (13) Garegg, P. J.; Samuelsson, B. *J. Chem. Soc., Perkin Trans. 1* **1980**, 2866.
- (14) Yadav, J. S.; Shekharam, T.; Gadgil, V. R. *Chem. Commun.* **1990**, 843.
- (15) Shi, H.; Liu, H.; Bloch, R.; Mandville, G. *Tetrahedron: Asymmetry* **2002**, *13*, 1423.
- (16) Hansen, T. M.; Florence, G. J.; Lugo-Mas, P.; Chen, J.; Abrams, J. N.; Forsyth, C. J. *Tetrahedron Lett.* **2003**, *44*, 57.
- (17) **Important Note:** Under these conditions, we find that **27** is always formed alongside approximately 14–17% of a lactone migration product that is difficult to remove at this stage; the latter impurity arises from attack of the C(8)-OH in **27** on its own lactone carbonyl.

7 $\xrightarrow[\text{CH}_2\text{Cl}_2, -40^\circ\text{C}, 2\text{ min}]{\text{17. SH SH (10 equiv), BF}_3\cdot\text{Et}_2\text{O (1.13 equiv)}}$ **27**

27 $\xrightarrow[\text{THF, } -78^\circ\text{C}]{\text{20. LiN(SiMe}_3)_3 (2.01\text{ equiv), 8 (3 equiv), (67\%)}}$ **29**

29 $\xrightarrow[\text{DMF, } 0^\circ\text{C}, 0.5\text{ h, then add MeI (20.8 equiv), stir at } 0^\circ\text{C}, 2\text{ h (89\%)}}]{\text{21. NaH (1.14 eq.)}}$ **30**

30 $\xrightarrow[\text{(MeO)}_3\text{CH (4:1), } \Delta, 48\text{ h (74\%)}}]{\text{22. PPTS (0.1 equiv), MeOH, (MeO)}_3\text{CH}}$ **31**

31 $\xrightarrow[\text{CH}_2\text{Cl}_2, -78^\circ\text{C}, 20\text{ min, quench at } -78^\circ\text{C}]{\text{24. Ti}_2\text{O (2 equiv), Et}_3\text{N (4 equiv)}}$ **6**

6 $\xrightarrow[\text{warm to } 0^\circ\text{C over 2 h (81\%)}}]{\text{25. KN(SiMe}_3)_2 (20\text{ equiv), PhMe, } -78^\circ\text{C}, \text{ 2 (20 equiv)}}$ **32**

32 + **33** $\xrightarrow[\text{THF, HCHO (g), } -78^\circ\text{C}, 10\text{ min, then stir 0.5 h}]{\text{26. LiN(SiMe}_3)_2 (1.56\text{ equiv.)}}$ **34**

34 $\xrightarrow[\text{CH}_2\text{Cl}_2, 0^\circ\text{C}, 1\text{ h, then add DBU (6.13 equiv) in THF, stir 1 h (69\% over 2 steps)}]{\text{27. MsCl (4.1 equiv), Et}_3\text{N (6.6 equiv.)}}$ **35**

35 $\xrightarrow[\text{Hoveyda-Grubbs Type II (54\%)}, \Delta, 14\text{ h}]{\text{28. PhMe, N-Mes-N-Mes (20 mol\%)}}$ **4**

4 $\xrightarrow[\text{(1.8), rt, 16 h (82\%)}}]{\text{29. 6 M aqueous HCl:THF}}$ **(+)-Eremantholid A**

Org. Lett., Vol. 9, No. 7, 2007